GoodRx Holdings (GDRX) Capital Expenditures (2019 - 2026)

GoodRx Holdings has disclosed Capital Expenditures across 8 years of filings, most recently posting $14.0 million for Q2 2026.

• In Q2 2026, Capital Expenditures fell 21.63% year-over-year to $14.0 million; the TTM figure through Jun 2026 stood at $65.4 million (down 8.66% YoY), while the FY2025 annual figure was $70.5 million, up 2.01% from the prior year.
• Capital Expenditures came in at $14.0 million for Q2 2026 at GoodRx Holdings, down from $20.5 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $21.7 million in Q1 2025 to a low of $10.7 million in Q1 2022.
• Average Capital Expenditures over 5 years is $15.6 million, with a median of $14.9 million recorded in 2022.
• Year-over-year, Capital Expenditures soared 84.89% in 2022 and decreased 21.63% in 2026.
• Over 5 years, Capital Expenditures stood at $15.1 million in 2022, then declined by 17.68% to $12.5 million in 2023, then soared by 32.25% to $16.5 million in 2024, then decreased by 11.49% to $14.6 million in 2025, then declined by 3.72% to $14.0 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $14.0 million in Q2 2026, $20.5 million in Q1 2026, and $14.6 million in Q4 2025.